[Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)]

Urologe A. 2017 Sep;56(9):1185-1186. doi: 10.1007/s00120-017-0464-7.
[Article in German]
No abstract available

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Androstenes / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / standards
  • Carcinoma / drug therapy*
  • Carcinoma / secondary*
  • Humans
  • Male
  • Medical Oncology / standards*
  • Practice Guidelines as Topic
  • Prednisone / therapeutic use*
  • Prostatic Neoplasms / drug therapy*
  • Treatment Outcome
  • Urology / standards

Substances

  • Androgen Antagonists
  • Androstenes
  • abiraterone
  • Prednisone